The answer depends on your diagnosis — not just which drug you're prescribed. Medicare covers GLP-1s for type 2 diabetes but generally excludes them for weight loss alone.
The exclusion traces back to the Medicare Modernization Act of 2003, which explicitly prohibited Medicare Part D from covering drugs used for weight loss or weight gain. This law predates modern GLP-1 medications by nearly 20 years, and has not been updated despite the FDA approving Wegovy and Zepbound specifically for obesity treatment.
The Treat and Reduce Obesity Act, which has bipartisan support in Congress, would repeal this exclusion. As of May 2026, it has not been enacted into law, though it has passed through committee votes.
In 2024, the FDA approved Wegovy for a new indication: reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight. Because this is a cardiovascular indication — not a weight loss indication — Medicare Part D plans may be required to cover it for qualifying patients.
To potentially qualify for Wegovy coverage under Medicare's cardiovascular exception, you must have: established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease) AND a BMI ≥27. Your prescriber should document the cardiovascular indication specifically.
If you have a type 2 diabetes diagnosis, Medicare Part D covers GLP-1 receptor agonists as prescription drugs. Your cost depends on your specific plan's formulary tier placement. Ozempic and Mounjaro are typically placed on Tier 3 or Tier 4, with monthly out-of-pocket costs of $50–$150 after coverage, subject to deductible. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025), total annual cost is now capped for Part D enrollees.
Medicare patients who need GLP-1 medications for weight loss but don't qualify for coverage have several options:
Yes — when prescribed for type 2 diabetes. Most Part D plans cover Ozempic on Tier 3 or Tier 4. It is not covered for weight loss alone.
Not for weight loss under current law. However, Wegovy may be covered when prescribed for cardiovascular risk reduction in patients with established CVD and obesity or overweight.
Yes — for type 2 diabetes. Zepbound (tirzepatide for obesity) is generally not covered under Medicare.
Proposed legislation that would require Medicare to cover FDA-approved anti-obesity medications. As of May 2026, it has not been enacted into law.